Medicago’s COVID-19 vaccine – approved during February in Canada – is facing limited growth in the near term after the World Health Organization said it would not review the vaccine because the company is partly owned by U.S.-Swiss tobacco company Philip Morris, health experts say.
Medicago’s vaccine on February 24 became the world’s first plant-based shot approved against COVID-19 after Health Canada cleared Covifenz for use in adults.
Medicago and GlaxoSmithKline reported positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant.